Study on the Preferences for PCI Implantation Devices Among Doctors and Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorXijing Hospital

About this trial

The contemporary percutaneous treatment of coronary artery disease typically involves initial lesion preparation with balloon angioplasty, followed by the deployment of a drug-eluting stent (DES) to provide an immediate scaffold and reduce the long-term risk of restenosis. However, stent implantation continues to present notable challenges, primarily due to the metallic scaffold left behind. Compared to DES, drug-coated balloons (DCB) provide a direct release of antiproliferative drugs into the vessel wall, preventing coronary restenosis after angioplasty and limiting the risk of stent-related events. DCBs are an established treatment option for in-stent restenosis and small vessels. However, the REC-CAGEFREE I trial demonstrated that a strategy of DCB angioplasty with rescue stenting did not achieve non-inferiority compared with the intended DES implantation in patients with de novo, non-complex coronary artery disease (CAD), irrespective of vessel diameter.

Previous studies have mainly focused on the efficacy of PCI strategies in reducing adverse event rates, while less attention has been paid to patients' willingness regarding stent implantation. The AHA conducted a systematic review on depression and poor prognosis among patients with acute coronary syndrome (ACS), concluding that health organizations should consider depression as an official risk factor for poor prognosis after ACS. A prior study of patients with coronary artery disease after stent implantation found that their anxiety stemmed primarily from concerns about the stent's long-term effects and its impact on their social interaction. However, data regarding patients' preferences on the selection of DES or DCB is scarce, and whether the psychological impact would differ between DES- or DCB-treated patients is still unknown. This study aimed to investigate the preferences of patients, as well as medical staff, for DES or DCB-based PCI.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with acute or chronic coronary syndrome who have undergone percutaneous coronary intervention;

Patients who can understand the purpose of this trial and are willing to participate in the preference questionnaire.

Healthcare providers who treat patients with coronary artery disease.

Disqualifiers

Aged < 18 years;

Inability to understand the questionnaire or presence of cognitive impairment.

Trial population

Healthcare providers and patients with CAD

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Questionnaire

    Other intervention

    A questionnaire regarding the preference of DCB or DES-based PCI among patients with CAD and medical staff

Treatment groups

600 Participants
are divided into 1 treatment group
Group A: Subjects1 intervention

Trial outcomes

Primary outcomes

1

Maximum acceptable risk in the trade-off of death

To avoid permanent metallic stent implantation, the maximum acceptable increase in risk for patients and medical staff in choosing DCB treatment.

Time frame
Before discharge
2

Maximum acceptable risk in the trade-off of stroke

To avoid permanent metallic stent implantation, the maximum acceptable increase in risk for patients and medical staff in choosing DCB treatment.

Time frame
Before discharge
3

Maximum acceptable risk in the trade-off of myocardial infarction

To avoid permanent metallic stent implantation, the maximum acceptable increase in risk for patients and medical staff in choosing DCB treatment.

Time frame
Before discharge
4

Maximum acceptable risk in the trade-off of cardiopulmonary resuscitation

To avoid permanent metallic stent implantation, the maximum acceptable increase in risk for patients and medical staff in choosing DCB treatment.

Time frame
Before discharge

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.